Citius Pharmaceuticals, Inc. (CTXR)
USD 2.59
(-5.13%)
USD 2.59
(-5.13%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 194.31 Thousand | 179.67 Thousand | 164.86 Thousand | 152.36 Thousand | 893.00 | 1753.00 |
| Gross Profit | -194.31 Thousand | -179.67 Thousand | -164.86 Thousand | -152.36 Thousand | -893.00 | -1753.00 |
| Operating Expenses | 36.73 Million | 33.31 Million | 23.53 Million | 17.71 Million | 15.59 Million | 13.78 Million |
| Selling, General and Administrative Expenses | 21.91 Million | 15.66 Million | 11.29 Million | 8.89 Million | 7 Million | 7.22 Million |
| Research and Development Expenses | 14.81 Million | 17.65 Million | 12.24 Million | 8.81 Million | 8.59 Million | 6.56 Million |
| Other Expenses | - | 1.45 Million | 59.91 Thousand | 110.2 Thousand | 715.98 Thousand | 1.26 Million |
| Cost and Expenses | 36.73 Million | 33.31 Million | 23.53 Million | 17.71 Million | 15.59 Million | 13.78 Million |
| Operating Income | -36.73 Million | -33.31 Million | -23.53 Million | -17.71 Million | -15.59 Million | -13.78 Million |
| Interest Expense | - | 251.39 Thousand | 10.83 Thousand | 15.67 Thousand | 16.44 Thousand | 15.83 Thousand |
| Income Tax Expense | 576 Thousand | 576 Thousand | 70.75 Thousand | 125.88 Thousand | 16.44 Thousand | 1.28 Million |
| Earnings before Tax | -31.96 Million | -33.06 Million | -23.05 Million | -17.54 Million | -15.56 Million | -12.53 Million |
| Net Income | -32.54 Million | -33.64 Million | -23.12 Million | -17.67 Million | -15.57 Million | -12.53 Million |
| Earnings Per Share Basic | -0.22 | -0.23 | -0.21 | -0.45 | -0.77 | -1.17 |
| Earnings Per Share Diluted | -0.22 | -0.23 | -0.21 | -0.45 | -0.77 | -1.17 |
| Weighted Average Shares Outstanding | 151.29 Million | 146.08 Million | 108.59 Million | 39.16 Million | 20.16 Million | 10.73 Million |
| Weighted Average Shares Outstanding (Diluted) | 151.29 Million | 146.08 Million | 108.59 Million | 39.16 Million | 20.16 Million | 10.73 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -36.72 Million | -32.88 Million | -22.87 Million | -17.38 Million | -15.54 Million | -13.78 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 52.84 Thousand | 52.07 Thousand | 51 Thousand | 49.96 Thousand | 194.31 Thousand | 49.01 Thousand |
| Gross Profit | -52.84 Thousand | -52.07 Thousand | -51 Thousand | -49.96 Thousand | -194.31 Thousand | -49.01 Thousand |
| Operating Expenses | 10.58 Million | 10.91 Million | 9.34 Million | 10.12 Million | 36.73 Million | 8.67 Million |
| Selling, General and Administrative Expenses | 7.81 Million | 7.31 Million | 6.71 Million | 7.24 Million | - | 4.9 Million |
| Research and Development Expenses | 2.76 Million | 3.6 Million | 2.62 Million | 2.88 Million | - | 3.76 Million |
| Other Expenses | 3.06 Million | 2.38 Million | 3.05 Million | 6.61 Million | 3.58 Million | 1.17 Million |
| Cost and Expenses | 10.63 Million | 10.97 Million | 9.34 Million | 10.12 Million | 36.73 Million | 8.67 Million |
| Operating Income | -10.63 Million | -10.97 Million | -9.34 Million | -10.12 Million | -36.73 Million | -8.67 Million |
| Interest Expense | - | - | - | 4.1 Million | - | - |
| Income Tax Expense | 144 Thousand | 144 Thousand | 144 Thousand | 144 Thousand | 576 Thousand | 144 Thousand |
| Earnings before Tax | -10.42 Million | -8.4 Million | -9.08 Million | -9.79 Million | -31.96 Million | -8.33 Million |
| Net Income | -10.57 Million | -8.54 Million | -9.23 Million | -9.94 Million | -32.54 Million | -8.47 Million |
| Earnings Per Share Basic | -0.06 | -0.05 | -0.06 | -0.06 | - | -0.06 |
| Earnings Per Share Diluted | -0.06 | -0.05 | -0.06 | -0.06 | - | -0.06 |
| Weighted Average Shares Outstanding | 173.85 Million | 159.07 Million | 158.95 Million | 158.85 Million | 151.29 Million | 153.77 Million |
| Weighted Average Shares Outstanding (Diluted) | 173.85 Million | 159.07 Million | 158.95 Million | 158.85 Million | 151.29 Million | 153.77 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -10.58 Million | -10.91 Million | -9.28 Million | -10.07 Million | - | -8.62 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
DUERF
OKEPF
NOVO-B
9830
603341
5112